cTnI / CK-MB / MYO Combo Test

Description

This kit is used for the in vitro quantitative detection of Cardiac Troponin I (cTnI), Creatine Kinase MB (CK-MB), Myoglobin (MYO) concentration in human serum/plasma and whole blood samples.

Cardiac troponin I: cardiac troponin I (cTnI) is a subunit of the cardiac troponin complex that regulates actin and myosin interactions by regulating the activity of Ca²⁺ on rhabdomyosin atpase. When myocardial injury is released into the blood, elevation begins 4-6 hours later, and elevated troponin I remains in the blood for 6-10 days, providing a longer detection period. CTnI has high myocardial specificity and sensitivity, and is an ideal marker for myocardial infarction.

Myoglobin (MYO), an early marker of myocardial infarction, is elevated 1 hour after the onset of a heart attack.

Creatine kinase isoenzyme (ck-mb) has been recognized as the most effective diagnosis of acute myocardial infarction (AMI) since it begins to increase in the blood after 3-4 hours of myocardial injury, peaks 24 hours, and returns to normal within 3-4 days.

MYO is the diagnosis of acute myocardial infarction (acute myocardial infarction, AMI) early better indicators of cTnI is high specificity index for diagnosis of AMI, CK – MB is not MYO earlier than cTnI sensitive, but the diagnosis of AMI early infarction after a certain value. Clinical results showed that patients with acute myocardial infarction (AMI) could be misdiagnosed or missed in each single test. The combination of the three cardiac markers can improve the sensitivity and specificity of early detection of patients with acute myocardial infarction (AMI).

PRODUCT DETAILS